Your browser doesn't support javascript.
loading
Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
van Heerden, Jennifer Kate; Meintjes, Graeme; Barr, David; Zhao, Ying; Griesel, Rulan; Keene, Claire Marriott; Wiesner, Lubbe; Galileya, Lufina Tsirizani; Denti, Paolo; Maartens, Gary.
Affiliation
  • van Heerden JK; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Meintjes G; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Barr D; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Zhao Y; NHS Greater Glasgow and Clyde, Scotland, United Kingdom.
  • Griesel R; Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
  • Keene CM; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Wiesner L; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Galileya LT; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Denti P; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Maartens G; Médecins Sans Frontières, Cape Town, South Africa; and.
J Acquir Immune Defic Syndr ; 95(3): 260-267, 2024 03 01.
Article in En | MEDLINE | ID: mdl-38408216
ABSTRACT

BACKGROUND:

Tenofovir diphosphate (TFV-DP) concentration in dried blood spots is a marker of long-term adherence. We investigated the relationship between TFV-DP concentrations and virological outcomes in participants initiating tenofovir-lamivudine-dolutegravir (TLD) as first-line or second-line antiretroviral therapy.

SETTING:

Three primary care clinics in Khayelitsha, Cape Town, South Africa.

METHODS:

We conducted a post hoc analysis of 2 randomized controlled trials of participants initiating TLD. TFV-DP concentrations and viral loads were measured at 12, 24, and 48 weeks. Multivariable logistic regression was performed to assess the association with virological suppression (<50 copies/mL) per natural logarithm increase in TFV-DP concentration. Generalized estimating equations with logit link were used to assess associations with virological rebound. The Akaike Information Criterion and Quasi-likelihood Information Criteria were used to compare models built on continuous TFV-DP data to 4 previously defined concentration categories.

RESULTS:

We included 294 participants in the analysis, 188 (64%) of whom initiated TLD as second-line therapy. Adjusted odds ratios (95% CIs) of virological suppression were 2.12 (1.23, 3.75), 3.11 (1.84, 5.65), and 4.69 (2.81, 8.68) per natural logarithm increase in TFV-DP concentration at weeks 12, 24, and 48, respectively. In participants with virological suppression at week 12, the adjusted odds ratio for remaining virologically suppressed was 3.63 (95% CI 2.21 to 5.69) per natural logarithm increase in TFV-DP concentration. Models using continuous TFV-DP data had lower Akaike Information Criterion and Quasi-likelihood Information Criteria values than those using categorical data for predicting virological outcomes.

CONCLUSION:

TFV-DP concentrations in dried blood spots exhibit a dose-response relationship with viral load. Analyzing TFV-DP concentrations as continuous variables rather than conventional categorization may be appropriate.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Organophosphates / Piperazines / Pyridones / Adenine / HIV Infections / Anti-HIV Agents / Heterocyclic Compounds, 3-Ring Limits: Humans Country/Region as subject: Africa Language: En Journal: J Acquir Immune Defic Syndr / J. acquir. immune defic. syndr / Journal of acquired immune deficiency syndromes (1999) Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Organophosphates / Piperazines / Pyridones / Adenine / HIV Infections / Anti-HIV Agents / Heterocyclic Compounds, 3-Ring Limits: Humans Country/Region as subject: Africa Language: En Journal: J Acquir Immune Defic Syndr / J. acquir. immune defic. syndr / Journal of acquired immune deficiency syndromes (1999) Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2024 Document type: Article Affiliation country: Country of publication: